Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxycodone extended release - Assertio Therapeutics

Next Previous
X
Search
Drug Profile

Oxycodone extended release - Assertio Therapeutics

Alternative Names: AD ER oxycodone; EG-P114; Egalet-002; Opioid 2

Latest Information Update: 08 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Egalet
  • Developer Zyla Life Sciences
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 20 May 2020 Assertio Therapeutics has been merged with Zyla Life Sciences to form Assertio Therapeutics
  • 31 Dec 2018 Oxycodone extended release - Egalet is available for licensing as of 31 Dec 2018
  • 31 Dec 2018 Discontinued - Phase-III for Pain in USA (PO), until a partner is found to share development and regulatory costs

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top